200,000+ products from a single source!
sales@angenechem.com
133099-07-7 | 3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-, hydrobromide (1:1), (3S)-
CAS No: 133099-07-7 Catalog No: AG001496 MDL No:MFCD08141803
Product Description
Catalog Number:
AG001496
Chemical Name:
3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-, hydrobromide (1:1), (3S)-
CAS Number:
133099-07-7
Molecular Formula:
C28H31BrN2O2
Molecular Weight:
507.4619
MDL Number:
MFCD08141803
IUPAC Name:
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
InChI:
InChI=1S/C28H30N2O2.BrH/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26;/h1-12,19,25H,13-18,20H2,(H2,29,31);1H/t25-;/m1./s1
InChI Key:
UQAVIASOPREUIT-VQIWEWKSSA-N
SMILES:
NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2.Br
EC Number:
603-705-7
UNII:
CR02EYQ8GV
Properties
Complexity:
607
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
506.157g/mol
Formal Charge:
0
Heavy Atom Count:
33
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
507.472g/mol
Monoisotopic Mass:
506.157g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
55.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. | Expert opinion on drug metabolism & toxicology 20121101 |
| Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n). | The Analyst 20120807 |
| Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. | Annals of internal medicine 20120619 |
| Role of M2 and M3 muscarinic acetylcholine receptor subtypes in activation of bladder afferent pathways in spinal cord injured rats. | Urology 20120501 |
| Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors. | The Journal of pharmacology and experimental therapeutics 20111201 |
| Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol. | Urology 20111201 |
| Time-to-effect with darifenacin in overactive bladder: a pooled analysis. | International urogynecology journal 20111201 |
| Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. | Neurourology and urodynamics 20111101 |
| A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. | British journal of clinical pharmacology 20110801 |
| Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. | Journal of the American Geriatrics Society 20110301 |
| Patient experience with darifenacin - results of a short-term community-based survey in managing overactive bladder. | Current medical research and opinion 20110201 |
| Activation state of the M3 muscarinic acetylcholine receptor modulates mammalian odorant receptor signaling. | Science signaling 20110111 |
| Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. | Digestive diseases and sciences 20110101 |
| Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument. | Neurourology and urodynamics 20110101 |
| Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. | Urology 20101001 |
| Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. | Life sciences 20100731 |
| Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. | American journal of physiology. Gastrointestinal and liver physiology 20100701 |
| Comparison of human and porcine gastric clasp and sling fiber contraction by M2 and M3 muscarinic receptors. | American journal of physiology. Gastrointestinal and liver physiology 20100401 |
| Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. | American journal of physiology. Gastrointestinal and liver physiology 20091201 |
| Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study. | International urogynecology journal and pelvic floor dysfunction 20091101 |
| Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. | BJU international 20091001 |
| Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice. | British journal of pharmacology 20090401 |
| Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. | The Journal of pharmacology and experimental therapeutics 20090301 |
| In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. | British journal of pharmacology 20090301 |
| Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). | Neurourology and urodynamics 20090101 |
| Use of antimuscarinics in the elderly. | TheScientificWorldJournal 20090101 |
| Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. | Journal of cardiovascular pharmacology and therapeutics 20081201 |
| Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. | International journal of clinical practice 20081101 |
| Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. | International journal of clinical practice 20081101 |
| Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. | International urogynecology journal and pelvic floor dysfunction 20081001 |
| Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. | Clinical interventions in aging 20080901 |
| Interstitial granulomatous dermatitis associated with darifenacin. | Journal of drugs in dermatology : JDD 20080901 |
| Clinical relevance of health-related quality of life outcomes with darifenacin. | BJU international 20080701 |
| Activated cholinergic signaling provides a target in squamous cell lung carcinoma. | Cancer research 20080615 |
| A journey to continence: a case study of overactive bladder syndrome. | Urologic nursing 20080601 |
| A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. | International journal of clinical practice 20080401 |
| The effect of darifenacin on overactive bladders in female and male rabbits. | International urology and nephrology 20080101 |
| Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. | Neurourology and urodynamics 20080101 |
| Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. | Current medical research and opinion 20071101 |
| Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model. | European journal of pharmacology 20071031 |
| Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. | Current medical research and opinion 20071001 |
| [The recommendations of the Polish Gynecologic Society regarding the use of darifenacin, selective muscarinic antagonists in the treatment of overactive bladder]. | Ginekologia polska 20071001 |
| Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. | European urology 20070901 |
| Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. | European urology 20070901 |
| Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. | European urology 20070901 |
| Cholinergic activation of phasic activity in the isolated bladder: possible evidence for M3- and M2-dependent components of a motor/sensory system. | BJU international 20070901 |
| Pharmacologic management of overactive bladder. | Clinical interventions in aging 20070901 |
| Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. | European urology 20070801 |
| Update on drugs for overactive bladder syndrome. | Drug and therapeutics bulletin 20070601 |
| M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. | Cancer research 20070415 |
| [Treatment of overactive bladder in elderly and old people]. | Der Urologe. Ausg. A 20070401 |
| Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. | Expert opinion on pharmacotherapy 20070301 |
| Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. | The Journal of urology 20070201 |
| M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors. | Neurourology and urodynamics 20070101 |
| Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. | Biological & pharmaceutical bulletin 20070101 |
| [Darifenacine--Emselex]. | Journal de pharmacie de Belgique 20070101 |
| In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. | Life sciences 20061214 |
| New developments in the treatment of urinary incontinence. | Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20061201 |
| Treatment of overactive bladder in the aging population: focus on darifenacin. | Clinical interventions in aging 20061201 |
| Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. | BJU international 20061101 |
| Darifenacin: Pharmacology and clinical usage. | The Urologic clinics of North America 20061101 |
| Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? | Naunyn-Schmiedeberg's archives of pharmacology 20061101 |
| Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. | European urology 20060801 |
| [Anticholinergics for overactive bladder: does subtype selectivity play a role?]. | Der Urologe. Ausg. A 20060701 |
| Regulation of bladder muscarinic receptor subtypes by experimental pathologies. | Autonomic & autacoid pharmacology 20060701 |
| Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. | International urogynecology journal and pelvic floor dysfunction 20060501 |
| Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. | The American journal of medicine 20060301 |
| M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder. | The Journal of pharmacology and experimental therapeutics 20060201 |
| M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder. | The Journal of pharmacology and experimental therapeutics 20060201 |
| New drugs 06, part I. | Nursing 20060201 |
| Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. | International journal of clinical practice 20060101 |
| The clinical pharmacokinetics of darifenacin. | Clinical pharmacokinetics 20060101 |
| Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. | BJU international 20051101 |
| Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. | European urology 20050901 |
| Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. | World journal of urology 20050901 |
| QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. | Journal of clinical pharmacology 20050901 |
| Solifenacin and darifenacin for overactive bladder. | Obstetrics and gynecology 20050801 |
| Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. | European urology 20050701 |
| Darifenacin in the treatment of overactive bladder. | International journal of clinical practice 20050701 |
| Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder. | Naunyn-Schmiedeberg's archives of pharmacology 20050701 |
| Darifenacin in the treatment of overactive bladder. | Drugs of today (Barcelona, Spain : 1998) 20050701 |
| New treatment options for overactive bladder. | South Dakota journal of medicine 20050601 |
| A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. | BJU international 20050501 |
| Increased warning time with darifenacin: a new concept in the management of urinary urgency. | The Journal of urology 20050401 |
| Solifenacin and darifenacin for overactive bladder. | The Medical letter on drugs and therapeutics 20050314 |
| An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. | BJU international 20050301 |
| Assessment of cognitive function of the elderly population: effects of darifenacin. | The Journal of urology 20050201 |
| New drugs: palifermin, eszopiclone, and darifenacin hydrobromide. | Journal of the American Pharmacists Association : JAPhA 20050101 |
| [Overactive bladder]. | Krankenpflege Journal 20050101 |
| Mechanisms mediating cholinergic antral circular smooth muscle contraction in rats. | World journal of gastroenterology 20041115 |
| Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. | Expert opinion on investigational drugs 20041101 |
| Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. | Current urology reports 20041001 |
| Elevating our therapeutic expectations in overactive bladder. | Journal of the American Academy of Nurse Practitioners 20041001 |
| In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. | European journal of pharmacology 20040525 |
| Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. | European urology 20040401 |
| Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. | British journal of clinical pharmacology 20040201 |
| Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. | Life sciences 20040102 |
| Darifenacin: in the treatment of overactive bladder. | Drugs & aging 20040101 |
| Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. | British journal of clinical pharmacology 20031201 |
| Pharmacological effects of darifenacin on human isolated urinary bladder. | Pharmacology 20031201 |
| Update on overactive bladder: pharmacologic approaches on the horizon. | Current urology reports 20031001 |
| M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. | Naunyn-Schmiedeberg's archives of pharmacology 20020801 |
| Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. | European journal of pharmacology 19980522 |
| Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. | Journal of receptor and signal transduction research 19970101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.